CD20-targeted immunotherapies in B-cell malignancies: mechanistic and clinical advances.

Hasani R, Pourseif MM, Alizadeh E, Tohidkia MR, Rahmati M

Open source

DOI
10.1016/j.exphem.2026.105444
Published
2026 Aug
Container
Experimental hematology
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.exphem.2026.105444,
  title = {CD20-targeted immunotherapies in B-cell malignancies: mechanistic and clinical advances.},
  author = {Hasani R and Pourseif MM and Alizadeh E and Tohidkia MR and Rahmati M},
  year = {2026},
  journal = {Experimental hematology},
  doi = {10.1016/j.exphem.2026.105444},
  url = {https://doi.org/10.1016/j.exphem.2026.105444}
}

RIS

TY  - JOUR
TI  - CD20-targeted immunotherapies in B-cell malignancies: mechanistic and clinical advances.
AU  - Hasani R
AU  - Pourseif MM
AU  - Alizadeh E
AU  - Tohidkia MR
AU  - Rahmati M
PY  - 2026
JO  - Experimental hematology
DO  - 10.1016/j.exphem.2026.105444
UR  - https://doi.org/10.1016/j.exphem.2026.105444
ER  - 

APA

R, H., MM, P., E, A., MR, T., & M, R. (2026). CD20-targeted immunotherapies in B-cell malignancies: mechanistic and clinical advances.. Experimental hematology. https://doi.org/10.1016/j.exphem.2026.105444

Source records